Hims Peptide Catalyst: The Valuation Shift Nobody Saw Coming

2026-07-23 · 2 company · 6 thematic

sentiment

2 bull0 bear0 neu

speakers

Travis Hoium hosts the Asymmetric Investing podcast/YouTube channel and manages the Asymmetric portfolio. He conducts fundamental research using Fiscal AI and focuses on platform business models, healthcare technology, and consumer subscription businesses. He discloses holding Hims & Hers as one of his largest positions.

travis holly

Travis Holly runs Asymmetric Investing, a subscription newsletter and portfolio service where he buys stocks monthly. Hims & Hers is the largest position in the Asymmetric portfolio, which he claims has beaten the market.

quote

“Hims & Hers stock jumped as much as 13% today... The FDA panel who is looking into peptides has recommended that BPC 157... the recommendation here from this panel is that the FDA should allow compounders to actually produce BPC 157... Thi…”

—travis hoium

now playing · $HIMS

$HIMS···bullish· high· postravis hoium

Hoium sees HIMS as asymmetric bet on peptide tailwind and platform flywheel

FDA peptide panel recommendations for BPC-157 and KPV create a regulatory tailwind for compounded peptides, while Hims & Hers' integrated data-AI-platform flywheel and Eucalyptus…

$EUCALYPTUSbullish· mediumtravis holly

Eucalyptus acquisition gives Hims & Hers immediate Australia and Japan footprint

The Eucalyptus acquisition transforms Hims & Hers into a global healthcare platform with instant presence in Australia and Japan, adding international revenue diversification and…

←

▶ 0:00 · $HIMS · Hims Peptide Catalyst: The Valuation Shift Nobody Saw Coming

episode briefing

Asymmetric Investing